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methionine metabolism. Plasma homocysteine concentrations ([HCY]p) are ele-
vated (>13 mmol/L) in people with atrial fibrillation (AF) and can predict the recur-
rence of AF after cardioversion. This study aimed to validate a commercially
available human HCY assay for use in horses to develop reference intervals for
[HCY]p and compare [HCY]p in healthy horses and horses with AF.
Animals: Healthy horses (n ¼ 27) and horses with AF (n ¼ 55, 34 of which were car-
dioverted using transvenous electrical cardioversion).of Veterinary Cardiology is the emphasis of additional web-based materials permitting the
ics. These materials can be viewed (by those readers with subscription access) by going to
ce/journal/17602734. The issue to be viewed is clicked and the available PDF and image
ary Plus link. The supplementary material for a given article appears at the end of the page. To
ww.doi.org and enter the doi number unique to this paper which is indicated at the end of the
presented as a poster at ECEIM congress, Helsinki, Finland in November 2016 and as a short
of the Graduate School of Cellular and Biomedical Sciences, University of Bern in January
ics.uzh.ch (K.J. Mitchell).
.007
hts reserved.
tchell KJ, et al., Plasma homocysteine concentrations in healthy horses and horses with atrial
rdiology (2018), https://doi.org/10.1016/j.jvc.2018.04.007
2 K.J. Mitchell et al.Abbreviations
AF atrial fibrillation
[Creat]p plasma concentratio
HCY homocysteine
[HCY]p plasma concentratio
HHCY hyperhomocysteinem
LA left atrial
NSR normal sinus rhythm
QS quinidine sulphate
TVEC transvenous electric
Please cite this article in press as: Mi
fibrillation, Journal of Veterinary CaMaterials and methods: Blood samples were analysed for HCY using an automated
enzyme-cycling assay (Homocysteine Cobas C, Integra, Roche) and creatinine (com-
pensated Jaffe method). Assay linearity and precision were assessed, reference in-
tervals calculated and [HCY]p and creatinine compared between groups.
Results: The assay was precise (coefficient of variation 1.6e4.3%, n ¼ 10 repeti-
tions) and provided linear results (r ¼ 0.99 for spiked and natural samples) for a
range of [HCY]p. The reference interval for [HCY]p was 1.5e7.8 mmol/L. The plasma
concentration of homocysteine was 4.65  1.5 mmol/L (mean  standard deviation)
in healthy horses and 4.65  1.72 mmol/L in horses with AF (p¼0.99); [HCY]p was
not associated with recurrence of AF (n ¼ 18, p¼0.97). A weak, positive correlation
between plasma creatinine and [HCY]p was detected (r ¼ 0.295, p¼0.008,
r2 ¼ 0.11).
Conclusions: This assay allows precise measurement of [HCY]p in horses. Unlike in
people, [HCY]p is not increased in horses with AF and cannot predict AF recurrence.
This might be due to differences in the underlying pathological mechanisms of AF
development in people and horses.
ª 2018 Elsevier B.V. All rights reserved.n of creatinine
n of homocysteine
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Homocysteine (HCY), an amino acid produced from
cellular metabolism of methionine, is an important
biomarker of cardiovascular disease in humans [1].
Experimentally induced hyperhomocysteinaemia
(HHCY) is associated with structural and electrical
myocardial remodelling through many pathways,
including endothelial dysfunction, oxidative stress,
vascular remodelling, nitric oxide synthase induc-
tion, matrix metalloproteinase and N-methyl D-
aspartate receptor activation and interference
with Kþ and Ca2þ handling [1e3].
Several studies have shown that plasma con-
centrations of homocysteine ([HCY]p) are elevated
in some people with nonvalvular atrial fibrillation
(AF) and that preconversion [HCY]p > 13 mmol/L is
associated with an increased risk of AF recurrence
following successful conversion to normal sinus
rhythm (NSR) [4e8].
Currently, predictors of AF recurrence in
horses that have been successfully converted totchell KJ, et al., Plasma homoc
rdiology (2018), https://doi.orNSR are associated with historical information
(duration of arrhythmia >4 months and previous
episode of AF), echocardiographic abnormalities
detected after successful conversion (presence of
persistent left atrial (LA) stunning, mild-
moderate mitral insufficiency, increased LA size
indices) or electrophysiological characteristics
(AF cycle length) [9e12]. In horses with ‘lone’ AF,
the recurrence rate after treatment is reported
between 15 and 40%, but it is higher in horses
with >4 month duration of AF, mild or greater
mitral regurgitation and in horses with a history
of previous treatment for AF [10e12]. A reliable
preconversion assessment of the risk of AF
recurrence is difficult and relies heavily on the
experience of the treating clinician. With the
high costs and risks associated with treatment of
AF, having a more accurate assessment of the risk
of AF recurrence prior to treatment would be
useful.
There is limited knowledge about [HCY]p in
horses. Although the common lifestyle risk factors
for HHCY in humans such as smoking, alcoholism or
sedentary lifestyle are not transferable to equine
practice, possible causes of HHCY in horses include
dietary excess of methionine, genetic mutations
within the methionine-homocysteine metabolism
pathway, dietary deficiencies of folate, vitamin B2,
B6 or B12, increasing age or concurrent renal dis-
ease. Plasma concentrations of HCY have been
measured in horses using high-pressure liquid
chromatography [13e17], but this method is
costly, time consuming and not available in all
laboratories. Reference intervals for healthy
horses are not published, and no studies have been
performed in horses with AF.ysteine concentrations in healthy horses and horses with atrial
g/10.1016/j.jvc.2018.04.007
Homocysteine in horses with AF 3The aims of this study were to (a) validate the
use of an automated enzyme cycling assayd for the
detection of [HCY]p in horses and calculate refer-
ence intervals of [HCY]p for healthy horses, (b)
evaluate [HCY]p in horses with AF and assess if an
association between elevated [HCY]p and AF
recurrence exists in horses and (c) assess the
effect of plasma concentrations of creatinine
([Creat]p) and age on [HCY]p in horses.Animals
All examinations were performed according to
institutional ethical standards. A power analysis
performed prior to the start of the study indicated
that to detect a difference of two mmol/L, with a
power of 0.8 and alpha error of 0.05, 20 horses
would be required per group. Owners’ consent
was obtained for use of blood samples from
healthy horses while the clinical cases had blood
sampling performed as part of a routine patient
workup.
Healthy horses
Twenty-seven active, healthy horses with no evi-
dence of underlying disease based on history,
physical examination, including thorough car-
diothoracic auscultation and complete blood
count and biochemistry analysis were included in
the study. Sixteen of the 27 horses also had a
complete echocardiography examination [18e20]
performed with no abnormal findings. These
horses were enrolled in other studies at the Uni-
versity of Zurich that had been approved by the
district veterinary office of the canton Zurich,
Switzerland [21,22].e
Horses with atrial fibrillation
Fifty-five horses presented for evaluation of AF,
subsequently diagnosed by electrocardiography,
to the Vetsuisse Faculty Zurich (n ¼ 10), Vetsuisse
Faculty Bern (n ¼ 3) and Faculty of Veterinary
Medicine Ghent University (n ¼ 42) from
2014e2015 were included in the study. A full
echocardiographic examination was performed tod Homocysteine Cobas C INTEGRA 800 assay, Roche Diagnostics
International Ltd, Rotkreuz, Switzerland.
e Animal Use License 116/2014 for ‘Investigation of excitatory
amino acid concentrations in horses during exer-
cise’dSchwarzwald CC., Mitchell KJ. Veterinaeramt, Kanton
Zurich, Switzerland.
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Horses were considered to have ‘lone AF’ if no
macroscopic structural disease or haemodynami-
cally relevant valvular regurgitations were pres-
ent. Horses with evidence of macroscopic
structural disease (atrial or ventricular enlarge-
ment) or haemodynamically relevant (moderate-
severe) valvular regurgitations were classified as
having underlying cardiac disease. This assess-
ment was made by experienced equine cardiolo-
gists (GvL, CCS, DDC, CNdS and KJM) based on a
combination of subjective evaluation and objec-
tive measurements. Transvenous electrical car-
dioversion (TVEC) was performed in 34 horses,
and quinidine sulphate (QS) cardioversion was
performed in three horses [23,24]. Treatment
(TVEC or QS) was based on clinician assessment or
owner preference. The remaining 18 horses were
not treated, either because treatment was not
recommended or was declined by the owners.Materials and methods
All blood samples were collected in lithium heparin
tubes. Blood samples from all horses were col-
lected at rest, on presentation, centrifuged for
plasma separation within 30 min of collection, for
10 min at 4C. Plasma samples were stored at
20C or 80C (depending on the institution)
until batch analysis.
Additional blood samples were collected one
day after TVEC and between 4 and 12 days after
TVEC in a subset of horses.
The plasma samples were batch-analysed (100
samples per batch) over a two-week period. Sam-
ples with macroscopic haemolysis, icterus or
lipaemia were excluded. The analysis was per-
formed using an automated enzyme-cycling assay.d
Samples were analysed according to the manu-
facturer’s instructions. The reported measurement
range was 3e50 mmol/L. The assay was calibrated
at the start of each reagent lot and every 7 days
thereafter, and reagents were discarded if not
used after 4 weeks.
Plasma samples both naturally occurring and
spiked with known concentrations of HCYf were
used to determine linearity, and accuracy (per-
centage recovery) of the assay while within-run
precision was calculated as the coefficient of var-
iation for repeated sample analysis (n ¼ 10
repeats) at a range of different concentrations.f DL-Homocysteine, Sigma-Aldrich pharmaceuticals (now
Merck), Darmstadt, Germany.
ysteine concentrations in healthy horses and horses with atrial
g/10.1016/j.jvc.2018.04.007
4 K.J. Mitchell et al.Plasma creatinine concentrations were deter-
mined using the compensated Jaffe method run on
an established automated analyser.g
Statistical analysis
Reference intervals were calculated using a dedi-
cated software package.h Distribution of the data
was checked visually using raw data with dot, box-
and-whisker and normal probability plots and his-
tograms. The 90% confidence intervals of the limits
of the reference intervals were determined using a
bootstrap method.
Data for the comparison between groups were
analysed for normality using the Shapiro-Wilk and
equal variance tests and visually inspected using
dot plots, histograms and normal probability plots
of residuals. The data were considered normally
distributed. An unpaired Student t-test was used
to compare [HCY]p in healthy horses to all horses
with AF. A repeated measures analysis of variance
was used to compare [HCY]p in horses before, 1
day and 4e12 days after TVEC, while a one-way
analysis of variance was used to analyse the dif-
ference in admission [HCY]p between groups of
healthy horses, horses remaining in AF without
treatment and treated horses with and without AF
recurrence. Associations between [HCY]p, [Cre-
at]p, group and age were assessed by comparing
linear models. The linear model with the lowest
Akaike information criterion was considered the
most representative. The effect of each variable
([Creat]p, age and group) was assessed using a Chi-
squared test. Statistical significance was set at
p<0.05.
Statistical analysis was performed using Graph-
Pad Prism (version 7.01), Sigmaplot (version 12.3)
and R (version 3.3.2)/Rstudio (version 1.0.136).Results
The healthy horses (n ¼ 27) were predominately
Warmbloods (n ¼ 21) with two Thoroughbreds, two
Arabs, a Standardbred and a Freiberger. The mean
age was 10 years (minemax: 3e23 years). There
were 20 geldings and seven mares.
The horses with AF (n ¼ 55) were predominately
Warmbloods (n ¼ 46) with two Irish sport horses,g Roche Cobas INTEGRA 800 analyser, Roche Diagnostics
International, Rotkreuz Switzerland.
h Reference Value Advisor v2.0 add-in for Microsoft Excel
2010, Biostatistiques, Ecole Nationale Veterinaire de Toulouse,
France.
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mean age was 12 years (minemax: 4e21 years).
There were 31 geldings, 12 mares and eight stal-
lions. Breed, age or sex data were not available for
four horses. ‘Lone AF’ was diagnosed in 37 horses,
with 18 horses considered to have underlying car-
diac disease. All 18 had LA, right atrial or biatrial
enlargement, with nine having concurrent left
ventricular, right ventricular or biventricular
enlargement. Haemodynamically relevant mitral
regurgitation was diagnosed in 10 horses, while
one horse each had relevant tricuspid or aortic
regurgitation. Two horses presented with signs of
congestive heart failure while a single horse had
evidence of primary pulmonary hypertension. Of
horses with underlying structural disease, eightFigure 1 Linearity under serial dilutions of (a) natural
(10.6 mmol/L) and (b) spiked (35 mmol/L) concentrations
of homocysteine in equine plasma. Measured values
were significantly correlated to the expected values for
all samples. r ¼ Pearson’s correlation coefficient; r2 ¼
linear regression goodness-of-fit; HCY ¼ homocysteine.
ysteine concentrations in healthy horses and horses with atrial
g/10.1016/j.jvc.2018.04.007
Figure 2 Comparison of [HCY]p in healthy horses and
horses with AF. There was no difference between groups
(p¼0.99, Student t-test). Dotted line represents the
upper limit of the reference interval for healthy horses.
[HCY]p ¼ plasma homocysteine concentration;
AF ¼ atrial fibrillation.
Homocysteine in horses with AF 5were converted while 10 remained in AF as treat-
ment was not recommended or was declined by
the owner.
Cardioversion to NSR was successfully per-
formed 39 times (36 different horses), 37 times
using TVEC, two using QS. One horse died from
ventricular fibrillation during QS treatment before
conversion to NSR. Three horses were included and
treated twice with TVEC due to AF recurrence
within the study period (July 2014eDec 2015).
Follow-up blood samples were available for 28
horses (30 treatments), one day and 4e12 days
after TVEC. At follow-up (obtained a minimum 16
months and maximum 3 years after therapy), 18/
36 horses (50%) were known to have AF recurrence
(6/8 [75%] with underlying cardiac disease and 12/
28 [43%] with ‘lone’ AF).
The linearity of the assay for both natural (serial
dilutions of 10.6 mmol/L [HCY]p) and spiked (serial
dilutions of 35 mmol/L [HCY]p) samples was
excellent (r ¼ 0.99, p<0.0001, r2 ¼ 0.99) (Fig. 1a/
b). The accuracy (percent recovery) was
102.5e104.4% for the spiked dilutions and
91.5e98.6% for the natural dilutions (Table 1). The
within-run precision (coefficient of variation,
n ¼ 10 repeats) was 4.3% for [HCY]p of 3.9 mmol/L
and 1.6% for [HCY]p of 16.7 mmol/L.
The reference interval calculated for [HCY]p in
healthy horses was 1.5e7.8 mmol/L (90% con-
fidence interval for lower limit 0.8e2.3 mmol/L,
upper limit 6.9e8.6 mmol/L), with a mean of
4.65 mmol/L.
No differences in mean [HCY]p was found
between healthy horses (mean  standard devia-
tion: 4.65  1.5 mmol/L) and horses with AF
(4.65  1.72 mmol/L) (Fig. 2, p¼0.99) with only
two horses in AF having [HCY]p above the upper
limit of the reference interval (both horses were
considered to have ‘lone AF’). There was no dif-
ference in [HCY]p in horses with and without AF
recurrence, and horses remaining in AF were notTable 1 Accuracy (% recovery) of the assay determined
(10.6 mmol/L) concentrations of homocysteine in equine p
% Dilution Spiked
expected
(mmol/L)
Spiked
measured
(mmol/L)
% Difference %
Recove
20% 7.05 7.36 4.4 104.4
40% 14.10 14.68 4.1 104.1
60% 21.14 21.67 2.5 102.5
80% 28.19 29.44 4.4 104.4
100% 35.24
Results show the expected and measured concentrations at variou
Please cite this article in press as: Mitchell KJ, et al., Plasma homoc
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(Fig. 3, p¼0.97). Following TVEC, there was a
slight increase in [HCY]p 24 h after return to sinus
rhythm with four horses (three with ‘lone’ AF and
one with structural disease) at or above the upper
limit of the reference interval, but this was not
statistically significant (Fig. 4, p¼0.14). Thirteen
models combining [HCY]p, [Creat]p, age, group and
interactions between variables were tested. The
model with the lowest Akaike information criterion
(288.7) included only [HCY]p and [Creat]p. There
was a weak positive linear correlation between
[Creat]p and [HCY]p (Fig. 5, r ¼ 0.295, r2 ¼ 0.11,
p¼0.008) with a one mmol/L increase in [Creat]p
responsible for 0.023 mmol/L increase in [HCY]p.
There was no effect of age (p¼0.67), group
(p¼0.71) or interactions between group, age and
[Creat]p.by serial dilutions of spiked (35 mmol/L) and natural
lasma.
ry
Natural
expected
(mmol/L)
Natural
measured
(mmol/L)
% Difference % Recovery
2.11 1.93 8.5 91.5
4.22 4.12 2.4 97.6
6.33 5.98 5.5 94.5
8.44 8.32 1.4 98.6
10.55
s dilutions and the % recovery.
ysteine concentrations in healthy horses and horses with atrial
g/10.1016/j.jvc.2018.04.007
Figure 4 Comparison of [HCY]p in horses with AF
treated with transvenous electrical cardioversion (TVEC)
before, 1 day, and 4e12 days after the procedure. There
was no difference between groups (p¼0.14, repeated
measures one-way analysis of variance). The dotted line
represents the upper limit of the reference interval for
healthy horses. [HCY]p ¼ plasma homocysteine concen-
tration; AF ¼ atrial fibrillation.
Figure 3 Comparison of [HCY]p between healthy
horses, horses with AF that were treated by car-
dioversion and remained in normal sinus rhythm (no
recurrence), horses that had AF recurrence (recur-
rence), and horses that were not treated and remained
in AF (not treated). No differences were detected
between groups (p¼0.97, one-way analysis of variance).
Dotted line represents the upper limit of the reference
interval for healthy horses. [HCY]p ¼ plasma homo-
cysteine concentration; AF ¼ atrial fibrillation.
6 K.J. Mitchell et al.
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In this study, the automated enzymatic cycling
assay provided precise, accurate and linear
measurement of [HCY]p in horses. Healthy horses
have a narrow reference interval for [HCY]p that is
similar but slightly lower than that reported for
people and dogs. [25,26] Unlike what is seen in
some people with AF, horses with AF do not have
increased [HCY]p compared with healthy horses.
There is a weak effect of increasing creatinine
concentration on [HCY]p.
Having an HCY assay that is simple, fast and
reliable is important for both clinicians and
researchers. As 99% of the total [HCY]p is present
in the oxidised form and highly protein bound
(>90%), quantification of total [HCY]p has been
historically challenging [25,26]. The use of an
automated enzymatic cycling assay (in comparison
to the previously reported high-pressure liquid
chromatography methods) streamlines the process
considerably and, as shown in this study with
equine plasma, provides excellent diagnostic per-
formance at the clinical decision limits, similar to
that reported in other species [25,26].
This sample of healthy horses had a very narrow
reference interval. While the other studies meas-
uring [HCY]p in horses used the high-pressure liquid
chromatography method of quantification and did
not calculate reference intervals for healthy ani-
mals, the results for ponies (n ¼ 44,
1.3e14.7 mmol/L) and Thoroughbreds, Arabs and
Warmbloods (n ¼ 37, 2.4e6.2 mmol/L) were rela-
tively similar to the results obtained with the
enzymatic assay [13e17]. The automated enzy-
matic assay has faster run times and requires less
specialised personnel making it more practical for
regular use, although a large number of samples
may be required to provide an economical diag-
nostic service.
Increasingly, evidence exists at the cellular
level for a role of HCY inducing structural and
electrical remodelling events within the myocar-
dium and vasculature [2,3,27,28]. In people, HHCY
is considered a risk factor for many adverse car-
diovascular events such as coronary artery disease,
AF, stroke, cerebral haemorrhage and sudden
cardiac death [1,2,4e7]. Particularly, in people
with nonvalvular AF, elevated [HCY]p has been
reported a useful indicator for the increased risk of
AF recurrence after successful treatment. This
information can guide clinical decision-making,
instigation of specific therapy to attempt to
reduce [HCY]p in this subset of patients and pro-
vide additional information when assessing theysteine concentrations in healthy horses and horses with atrial
g/10.1016/j.jvc.2018.04.007
Figure 5 Correlation between [HCY]p and [Creat]p combined data from healthy horses (black dots) and horses in AF
(grey dots) (total n ¼ 84). [HCY]p ¼ plasma homocysteine concentration; [Creat]p ¼ plasma concentration of crea-
tinine; AF ¼ atrial fibrillation; r ¼ Spearman’s correlation coefficient; r2 ¼ linear regression goodness-of-fit.
Homocysteine in horses with AF 7cost/benefit ratio of attempting pharmacological
or electrical cardioversion or cardiac ablation
procedures [6].
In this study, horses with AF did not have ele-
vated [HCY]p when compared with healthy horses,
and there was no association with [HCY]p and AF
recurrence after successful treatment. This high-
lights the potential differences between species
and suggests, at least in part, different patho-
physiological mechanisms might underlie the
development of AF in horses. This study would
suggest that HHCY does not play an obvious role in
the development of AF in horses and [HCY]p cannot
be used to predict the risk of recurrence after
successful cardioversion.
Horses have a documented increased risk of AF
recurrence with greater than 4 months duration of
AF prior to treatment, altered atrial electro-
physiological properties and increased atrial size,
and when atrial-stunning persists 24 h after suc-
cessful conversion [9e12]. It is likely at the cellular
level, factors other than or in addition to HCYplay a
role in the electrical and microstructural remod-
elling that increase the risk of recurrence in horses.
Interestingly, in this study 43% of horses considered
to have ‘lone AF’ had recurrence between 16
months and 3 years after therapy. This is similar to
what has been previously been reported for horses
considered to have ‘lone AF’ [10e12]. WhenPlease cite this article in press as: Mitchell KJ, et al., Plasma homoc
fibrillation, Journal of Veterinary Cardiology (2018), https://doi.oranalysing the eight horses with evidence of struc-
tural disease, the frequency of recurrence was
much higher (75%). These data support the concern
that echocardiographic evidence of structural
heart disease carries a higher risk for reversion to
AF and should be one important factor when
deciding to proceed with cardioversion. The pre-
ponderance of Warmbloods in this study might also
be a factor in these outcomes.
Horses are unique in terms of developing AF, as
many horses with AF do not have clear echo-
cardiographic evidence of underlying disease
affecting the atria (e.g. haemodynamically rele-
vant valvular insufficiency), unlike is commonly
reported in humans and dogs [29,30]. Following
successful conversion of ‘lone AF’ in these horses,
echocardiographic alterations in LA size and
function have been reported [31] indicating a
degree of structural and electrical remodelling
occurs which is presumed to be directly related to
the AF. In people with non-valvular AF, there is
evidence of elevated [HCY]p correlated with
echocardiographic changes, in particular LA
enlargement [4,7]; in our study there was no evi-
dence of increased [HCY]p even in horses with
reported LA enlargement. Additionally, in people
with other types of cardiovascular disease, HHCY
has been associated with left ventricular enlarge-
ment and left ventricular systolic and diastolicysteine concentrations in healthy horses and horses with atrial
g/10.1016/j.jvc.2018.04.007
8 K.J. Mitchell et al.dysfunction [1,32]. Evaluation of the association
between structural cardiac disease and [HCY]p was
beyond the scope of this study. In the current
study, no attempt was made to standardise the
assessment of underlying cardiac disease between
clinicians and clinics, therefore, interactions
between structural changes to the myocardium
and the [HCY]p cannot be inferred.
It has been previously documented that both
age and renal disease can result in increased
[HCY]p [26]. In this current study, there was a weak
positive correlation between [Creat]p and [HCY]p
with 11% of the increase in [HCY]p being explained
by an increase in [Creat]p. This suggests that par-
ticularly in patients with severe azotaemia, [HCY]p
should be interpreted cautiously. There was no
association with increasing age and [HCY]p found in
this study. It is likely that factors such as genetic
mutations affecting methionine, folate or cobala-
min metabolism, a high protein or methionine rich
diet, folate or cobalamin deficiency, smoking and
leading a sedentary lifestyle contribute sig-
nificantly to the risk of developing both HHCY and
cardiovascular disease as people age, while in
contrast, horses lack exposure to many of these
known risk factors [26,33].
Other factors like lipaemia, icterus and hae-
molysis can also interfere with the accuracy of the
enzymatic assay [25]. For this reason, samples with
macroscopic haemolysis, icterus and lipaemia
were excluded from further analysis in the current
study.
Similarly, there is conflicting evidence over
whether to use ethylenediaminetetraacetic acid
(EDTA) plasma, lithium heparin plasma or serum
for the analysis although the information provided
by the company states that all sample types are
acceptable [25,26]. Regardless of the sample
choice, it is most important to cool the blood
sample on ice and separate the RBCs from the
plasma/serum within 30 min of sample collection,
to avoid release of HCY from damaged RBCs. Once
the sample is frozen, HCY remains stable for sev-
eral years regardless of storage temperature (20
or 80 C) and can withstand 5e10 freeze/thaw
cycles [26,34]. Future study planning should
ensure that the same blood sample type is ana-
lysed across the duration of the study.Conclusions
Healthy horses have narrow reference intervals for
[HCY]p. This automated assay provided accurate,
precise and linear measurement of [HCY]p in
equine plasma. Unlike in humans, [HCY]p is notPlease cite this article in press as: Mitchell KJ, et al., Plasma homoc
fibrillation, Journal of Veterinary Cardiology (2018), https://doi.orincreased in horses with AF and cannot be used to
predict the recurrence of AF after successful car-
dioversion. Further evaluation is required to assess
the relationship between structural heart disease
and [HCY]p in horses.Conflicts of Interest Statement
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